CURRENT TREATMENT PATTERNS AND SURVIVAL IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINDINGS FROM A BRIEF SURVEY OF EUROPEAN PHYSICIANS

被引：0
|
作者：
Davis, K. L. [1 ]
Lin, H. M. [2 ]
Zhang, S. [3 ]
Kaye, J. A. [4 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Millennium Pharmaceut Inc, Cambridge, MA USA
[3] Takeda Pharmaceut Int Inc, Deerfield, IL USA
[4] RTI Hlth Solut, Waltham, MA USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.1284
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN186
引用
收藏
页码：A1221 / A1221
页数：1
相关论文
共 50 条
  • [41] Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma
    Ehsan, Hamid
    Wahab, Ahsan
    Shah, Zunairah
    Sana, Muhammad Khawar
    Masood, Adeel
    Rafae, Abdul
    Hashmi, Hamza
    JOURNAL OF HEMATOLOGY, 2021, 10 (03) : 89 - 97
  • [42] Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
    Stewart, A. Keith
    FUTURE ONCOLOGY, 2015, 11 (15) : 2121 - 2136
  • [43] Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma
    Sheikh, Semira
    Lebel, Eyal
    Trudel, Suzanne
    FUTURE ONCOLOGY, 2020, 16 (34) : 2783 - 2798
  • [44] Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
    Fostier, Karel
    De Becker, Ann
    Schots, Rik
    ONCOTARGETS AND THERAPY, 2012, 5 : 237 - 244
  • [45] Selinexor for the treatment of patients with relapsed or refractory multiple myeloma
    Babar, Anum
    Babar, Maham
    Zubair, Hina
    Shahid, Arzu
    Rafique, Sana
    Bano, Maimona
    Waleed, Madeeha Subhan
    Khan, Maimoona
    Inayat, Arslan
    Safi, Danish
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (03) : 535 - 546
  • [46] TREATMENT RESPONSE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
    Ioana, I.
    Liviu, C.
    Maria, C.
    Claudiu, I.
    Maria, I.
    Mihai, I.
    Dacian, O.
    Ovidiu, P.
    Cristina, S.
    Despina, C.
    Hortensia, I.
    HAEMATOLOGICA, 2013, 98 : 614 - 614
  • [47] Correspondence: Cost of Treatment for Relapsed/Refractory Multiple Myeloma
    Abouzaid, Safiya
    Gibson, Craig
    Nagarwala, Yasir
    AMERICAN HEALTH AND DRUG BENEFITS, 2015, 8 (09):
  • [48] Current developments in the combination therapy of relapsed/refractory multiple myeloma
    Maples, Kathryn T.
    Joseph, Nisha S.
    Harvey, R. Donald
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (12) : 1021 - 1035
  • [49] Carfilzomib Dosing Patterns and Survival in Patients with Relapsed and Refractory Multiple Myeloma: An Analysis from US Community Oncology Practices
    Rifkin, Robert M.
    Fonseca, Eileen
    Chen, Yaozhu J.
    Fox, Patricia S.
    Browning, James E.
    Cong, Ze
    BLOOD, 2015, 126 (23)
  • [50] Use of pomalidomide-based regimens in relapsed/refractory multiple myeloma (RRMM) in four European countries - findings from PREAMBLE
    Goldschmidt, H.
    Moreau, P.
    Chen, C.
    Davis, C.
    Cook, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 280 - 281
12345